Liquidia Corporation
LQDAHeld by 2 specialist biotech funds
2 funds opened new positions. Next phase2 readout (Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)): Dec 2011. Short interest: 13.9% of float.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.